Clinically, RALD is characterized by splenomegaly, a relatively mild degree of peripheral lymphadenopathy, and autoimmunity. The autoimmune phenotype can present in childhood or adulthood and primarily includes autoimmune hemolytic anemia, ITP, and neutropenia. Some patients have a history of recurrent respiratory tract infections. It is unclear if increased risk for malignancy is part of RALD. Importantly, however, the clinical and laboratory phenotype resembles juvenile myelomonocytic leukemia. The high fatality rate of this childhood blood cancer puts it in sharp contrast when compared to the relatively benign and chronic course of RALD. Approximately 15-30% of patients diagnosed with JMML have somatic, activating<unk>  mutations. However, due to the difficulty in distinguishing JMML from RALD, it is possible a subset of patients treated for JMML actually have RALD and could therefore avoid the aggressive JMML treatment. This distinction is under investigation.
RAS-associated autoimmune leukoproliferative disorder
Thymoma-associated multiorgan autoimmunity
Fibrin-associated diffuse large B-cell lymphoma
ALK+ large B-cell lymphoma
Autoimmune lymphoproliferative syndrome
Epstein–Barr virus–associated lymphoproliferative diseases
X-linked lymphoproliferative disease
Nodal marginal zone B cell lymphoma